Christopher Sweeney

1.6k total citations
15 papers, 285 citations indexed

About

Christopher Sweeney is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Christopher Sweeney has authored 15 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Surgery. Recurrent topics in Christopher Sweeney's work include Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Renal cell carcinoma treatment (2 papers). Christopher Sweeney is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Renal cell carcinoma treatment (2 papers). Christopher Sweeney collaborates with scholars based in United States, United Kingdom and Germany. Christopher Sweeney's co-authors include Michael A. Gordon, Alan Sandler, Linda A. Battiato, Christopher Jordan, Isabelle Pouliquen, Michael Burgess, Christopher A. Slapak, Karen Fife, Dinesh P. de Alwis and Ajai K. Chaudhary and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Christopher Sweeney

15 papers receiving 279 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Sweeney United States 7 174 94 94 46 41 15 285
Theresa Dunn Germany 10 147 0.8× 195 2.1× 96 1.0× 95 2.1× 19 0.5× 14 421
D.J. Boote United Kingdom 5 162 0.9× 66 0.7× 29 0.3× 91 2.0× 73 1.8× 7 319
Ekaphop Sirachainan Thailand 12 264 1.5× 84 0.9× 80 0.9× 88 1.9× 25 0.6× 37 432
Gonzalo Gomez-Abuin Argentina 6 182 1.0× 94 1.0× 84 0.9× 78 1.7× 17 0.4× 10 350
Kyohei Watanabe Japan 10 220 1.3× 147 1.6× 216 2.3× 75 1.6× 9 0.2× 45 441
Yutaka Chuman Japan 12 438 2.5× 149 1.6× 72 0.8× 263 5.7× 43 1.0× 16 540
R. Déporte-Féty France 9 290 1.7× 203 2.2× 55 0.6× 26 0.6× 16 0.4× 12 434
T. Facchini France 9 303 1.7× 77 0.8× 90 1.0× 21 0.5× 26 0.6× 22 401
Suparna C. Clasen United States 8 179 1.0× 131 1.4× 43 0.5× 28 0.6× 10 0.2× 16 378

Countries citing papers authored by Christopher Sweeney

Since Specialization
Citations

This map shows the geographic impact of Christopher Sweeney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Sweeney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Sweeney more than expected).

Fields of papers citing papers by Christopher Sweeney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Sweeney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Sweeney. The network helps show where Christopher Sweeney may publish in the future.

Co-authorship network of co-authors of Christopher Sweeney

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Sweeney. A scholar is included among the top collaborators of Christopher Sweeney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Sweeney. Christopher Sweeney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Lage, Daniel E., M. Dror Michaelson, Christopher Sweeney, et al.. (2021). Symptom burden, functional status, and clinical outcomes of hospitalized patients with advanced genitourinary cancers.. Journal of Clinical Oncology. 39(6_suppl). 42–42. 1 indexed citations
2.
Hamid, Anis, Kathryn P. Gray, Ying Huang, et al.. (2018). Association of low PTEN expression by fluorescence immunohistochemistry (F-IHC) and lethal disease in men with surgically-treated prostate cancer (PrCa).. Journal of Clinical Oncology. 36(6_suppl). 15–15. 4 indexed citations
3.
Klotz, Laurence, Christopher Sweeney, Adam P. Dicker, et al.. (2017). PD24-07 EFFICACY AND SAFETY OF RADIUM-223 BY RADICAL LOCAL THERAPY AT INITIAL DIAGNOSIS: A RETROSPECTIVE SUBGROUP ANALYSIS OF ALSYMPCA TRIAL. The Journal of Urology. 197(4S). 2 indexed citations
4.
Harshman, Lauren C., Lillian Werner, Mari Nakabayashi, et al.. (2016). The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 34(2_suppl). 196–196. 1 indexed citations
5.
Sartor, Oliver, Daniel C. Fernandez, Michael J. Morris, et al.. (2015). Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.. Journal of Clinical Oncology. 33(7_suppl). 253–253. 9 indexed citations
6.
Chiorean, E. Gabriela, Christopher Sweeney, Hagop Youssoufian, et al.. (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 73(3). 595–604. 50 indexed citations
7.
8.
9.
O’Donnell, Elizabeth, Kathryn P. Gray, Praful Ravi, & Christopher Sweeney. (2013). A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT).. Journal of Clinical Oncology. 31(6_suppl). 324–324. 1 indexed citations
10.
Milowsky, Matthew I., Christian Dittrich, Satinder Jagdev, et al.. (2013). Final results of a multicenter, open-label phase II trial of dovitinib (TKI258) in patients with advanced urothelial carcinoma with either mutated or nonmutated FGFR3.. Journal of Clinical Oncology. 31(6_suppl). 255–255. 29 indexed citations
11.
12.
Hutson, Thomas E., Long H. Dang, Richard C. Lauer, et al.. (2012). Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors (Hoosier Oncology Group).. Journal of Clinical Oncology. 30(5_suppl). 373–373. 2 indexed citations
13.
Mita, Alain C., Chris H. Takimoto, Naseem J. Zojwalla, et al.. (2007). A phase I trial of the hemiasterlin analogue E7974 administered IV to patients with solid malignancies.. 6. 1 indexed citations
14.
Pan, Chong‐Xian, Patrick J. Loehrer, Paul R. Helft, et al.. (2005). A Phase II Trial of Irinotecan, 5-Fluorouracil and Leucovorin Combined with Celecoxib and Glutamine as First-Line Therapy for Advanced Colorectal Cancer. Oncology. 69(1). 63–70. 30 indexed citations
15.
Sandler, Alan, Michael A. Gordon, Dinesh P. de Alwis, et al.. (2004). A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy. Clinical Cancer Research. 10(10). 3265–3272. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Theresa Dunn Breakdown of academic impact, for papers by D.J. Boote Breakdown of academic impact, for papers by Ekaphop Sirachainan Breakdown of academic impact, for papers by Gonzalo Gomez-Abuin Breakdown of academic impact, for papers by Kyohei Watanabe Breakdown of academic impact, for papers by Yutaka Chuman Breakdown of academic impact, for papers by R. Déporte-Féty Breakdown of academic impact, for papers by T. Facchini Breakdown of academic impact, for papers by Suparna C. Clasen
Rankless by CCL
2026